Article
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?
International journal of molecular sciences - 28 Apr 2023
Cabrera-Serrano Antonio José, Sánchez-Maldonado José Manuel, Ter Horst Rob, Macauda Angelica, García-Martín Paloma, Benavente Yolanda, Landi Stefano, Clay-Gilmour Alyssa, Niazi Yasmeen, Espinet Blanca, Rodríguez-Sevilla Juan José, Pérez Eva María, Maffei Rossana, Blanco Gonzalo, Giaccherini Matteo, Cerhan James R, Marasca Roberto, López-Nevot Miguel Ángel, Chen-Liang Tzu, Thomsen Hauke, Gámez Irene, Campa Daniele, Moreno Víctor, de Sanjosé Silvia, Marcos-Gragera Rafael, García-Álvarez María, Dierssen-Sotos Trinidad, Jerez Andrés, Butrym Aleksandra, Norman Aaron D, Luppi Mario, Slager Susan L, Hemminki Kari, Li Yang, Berndt Sonja I, Casabonne Delphine, Alcoceba Miguel, Puiggros Anna, Netea Mihai G, Försti Asta, Canzian Federico, Sainz Juan
Abstract excerpt
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of GWAS-identified risk variants to predict disease progression and patient survival remains unexplored. Here, we evaluated whether 41 GWAS-identified risk variants for CLL could...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.